<DOC>
	<DOCNO>NCT02691533</DOCNO>
	<brief_summary>Study population : Patients admit see OPD ( Out Patient Department ) , Department Hepatology . Study design- Prospective Randomized Controlled Trial . Study period-January 2016 May 2017 Intervention- Subjects randomize 3 group Group A subject receive ω3 PUFA ( Polyunsaturated Fatty Acids ) ( 10 % Omegavan 100 ml ) . Group B- receive ω6 PUFA ( Polyunsaturated Fatty Acids ) ( 10 % Intralipid 100 ml ) . Group C -Placebo group Monitoring assessment- : - The following test do patient : - 1 . Complete clinical examination . 2 . Serum electrolytes- sodium , potassium , calcium , magnesium , phosphate level 3 . BUN ( Blood Urea Nitrogen ) 4 . Serum free fatty acid level 5 . Lipid profile . 6 . Arterial ammonia 7 . Arterial lactate 8 . Blood sugar serum insulin level</brief_summary>
	<brief_title>To Study Immunomodulating Effects Safety Profile ω3 ω6 PUFA Containing Intravenous Lipid Emulsion Patients With Acute Chronic Liver Failure</brief_title>
	<detailed_description />
	<mesh_term>Liver Failure</mesh_term>
	<mesh_term>End Stage Liver Disease</mesh_term>
	<mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
	<mesh_term>Soybean oil , phospholipid emulsion</mesh_term>
	<mesh_term>Fat Emulsions , Intravenous</mesh_term>
	<criteria>Acute Chronic Liver Failure ( ACLF ) patient age 18 year Patients tolerate enteral nutrition Patients overt sepsis fever , sterile blood urine culture , procalcitonin &lt; 2 Active ongoing GI bleed Allergy soya oil , egg , peanut ingredient intralipid . Comorbidities like Diabetes mellitus , hyperlipidemia , CAD hypothyroidism . Renal failure ( S.creatinine &gt; 2.5mg % ) Pregnancy Patients shock require vasopressor support Patients anticoagulant Refusal participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Acute</keyword>
</DOC>